The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Sun., Apr. 18, 5:36 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #51. Sangamo BioSciences Ceregene

Acquirer: Sangamo BioSciences (NASDAQ:SGMO)
Acquiree: Ceregene
Details: Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. Sangamo will host a teleconference at 8:30 am ET tomorrow, Tuesday, August 27, 2013, to discuss the acquisition and provide a general business overview.

Sangamo BioSciences is a clinical stage biotechnology company focused on translating science into genomic medicines using its platform technologies in gene therapy and in vivo genome regulation. Co. is focused on these therapeutic areas: inherited metabolic diseases, central nervous system diseases and inflammatory and autoimmune diseases. Co. is evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. Under its agreement with Sanofi Genzyme, Co. is developing ST-400 and BIVV-003, ex vivo gene-edited cell therapies, for hemoglobinopathies including transfusion dependent beta thalassemia and sickle cell disease.

SGMO SEC Filing Email Alerts Service

Open the SGMO Page at The Online Investor »

Company Name: 
Sangamo Therapeutics Inc
Number of ETFs Holding SGMO: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the SGMO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Buy (3.11 out of 4)
35th percentile
(ranked lower than approx. 65% of all stocks covered)

Analysts' Target Price:
SGMO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 51 of 83 Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.